Steve Bray

In over 15 years of research experience Steve has gained broad expertise in applying genomics to better understand disease. Steve received a BS in biochemistry from Brigham Young University in 2000 and a PhD in genetics from Duke University in 2006. His doctoral research at Duke University and subsequent post-doctoral training at Emory University focused on the genetic control of neurological function including studies of chemosensory function, fragile X syndrome and Alzheimer’s disease.

Additionally, his population genetic analyses uncovered unique genetic characteristics of founder populations. In 2011, Steve joined Eli Lilly and Company as a genetics research scientist utilizing DNA sequencing of tumor samples to better understand the genomic landscape of cancer and associated drug response. In these efforts he helped uncover cancer mutations that predict positive treatment responses or resistance to therapies.